ITCI * logo

Intra-Cellular Therapies BMV:ITCI * Stock Report

Last Price

Mex$2.65k

Market Cap

Mex$285.3b

7D

0%

1Y

n/a

Updated

02 Apr, 2025

Data

Company Financials +

Intra-Cellular Therapies, Inc.

BMV:ITCI * Stock Report

Market Cap: Mex$285.3b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ITCI * Stock Overview

A biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. More details

ITCI * fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 64.9% below our estimate of its fair value

Earnings are forecast to grow 50.53% per year

Earnings have grown 10.9% per year over the past 5 years

Risk Analysis

Shares are highly illiquid


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Intra-Cellular Therapies, Inc. Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$20.9b

Sichuan Biokin PharmaceuticalLtd

SHSE:688506

CN¥105.5b

Shionogi

TSE:4507

JP¥1.9t

Shanghai Allist Pharmaceuticals

SHSE:688578

CN¥37.8b

Price History & Performance

Summary of share price highs, lows and changes for Intra-Cellular Therapies
Historical stock prices
Current Share PriceUS$2,648.00
52 Week HighUS$2,648.00
52 Week LowUS$1,119.00
Beta0.70
1 Month Change0.84%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO167.20%

Recent News & Updates

Recent updates

Shareholder Returns

ITCI *MX PharmaceuticalsMX Market
7D0%-2.3%1.2%
1Yn/a-11.8%-5.0%

Return vs Industry: Insufficient data to determine how ITCI * performed against the MX Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ITCI * performed against the MX Market.

Price Volatility

Is ITCI *'s price volatile compared to industry and market?
ITCI * volatility
ITCI * Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in MX Market9.0%
10% least volatile stocks in MX Market2.8%

Stable Share Price: ITCI *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine ITCI *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002860Sharon Mateswww.intracellulartherapies.com

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing lumateperone, which is in Phase 3 clinical trial for the treatment of major depressive disorder, as well as schizophrenia in pediatric patients, bipolar disorder, and irritability associated with autism spectrum disorder.

Intra-Cellular Therapies, Inc. Fundamentals Summary

How do Intra-Cellular Therapies's earnings and revenue compare to its market cap?
ITCI * fundamental statistics
Market capMex$285.28b
Earnings (TTM)-Mex$1.52b
Revenue (TTM)Mex$13.85b

20.6x

P/S Ratio

-187.8x

P/E Ratio

Is ITCI * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ITCI * income statement (TTM)
RevenueUS$680.85m
Cost of RevenueUS$293.08m
Gross ProfitUS$387.77m
Other ExpensesUS$462.44m
Earnings-US$74.68m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.70
Gross Margin56.95%
Net Profit Margin-10.97%
Debt/Equity Ratio0%

How did ITCI * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/02 23:16
End of Day Share Price 2025/03/10 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Intra-Cellular Therapies, Inc. is covered by 8 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert HazlettBTIG
Jason ButlerCitizens JMP Securities, LLC
Corinne JohnsonGoldman Sachs